Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

TREM2 interacts with TDP-43 and mediates microglial neuroprotection against TDP-43-related neurodegeneration
Zhao, Shuyi , Zhang, Lingxin , Bosco, Dale B. , Martens, Yuka A. , Zhao, Na , Zhuang, Yongxian , Wang, Liewei , Mattson, Mark P. , Zhao, Na , Xie, Manling , Liu, Yong , Pang, Yuan‐Ping , Sheth, Udit , Liu, Chia‐Chen , Dickson, Dennis W. , Bu, Guojun , Wu, Long‐Jun

Mayo Clinic

No container title available | January 15, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-133413/v1 Get It

Abstract Triggering receptor expressed on myeloid cell 2 (TREM2) is a surface receptor that, in the central nervous system, is exclusively expressed on microglia. TREM2 variants have been linked to increased risk for neurodegenerative diseases, but the functional effects of microglial TREM2 remain largely unknown. To this end, we investigated TAR-DNA binding protein 43 kDa (TDP-43)-related neurodegenerative disease via viral-mediated expression of human TDP-43 protein (hTDP-43) in mice or inducible expression of hTDP43 with defective nuclear localization signals in transgenic mice. We found that TREM2 deficiency impaired microglia phagocytic clearance of pathological TDP-43, and enhanced neuronal damage and motor function impairments. Mass cytometry analysis revealed that hTDP-43 induced a TREM2-dependent subpopulation of microglia with high CD11c expression and higher phagocytic ability. Using mass spectrometry, we further demonstrated an interaction between TDP-43 and TREM2, in vitro and in vivo, in hTDP-43-expressing transgenic mouse brains. We computationally identified the region within hTDP-43 that interacts with TREM2 and observed the potential interaction in ALS patient tissues. Our data reveal the novel interaction between TREM2 and TDP-43, highlighting that TDP-43 is a potential ligand for microglial TREM2 and the interaction mediates neuroprotection of microglial TREM2 in TDP-43-related neurodegeneration.
Demographic Trends From 2005 to 2015 Among Physicians With Accreditation Council for Graduate Medical Education–Accredited Anesthesiology Training and Active Medical Licenses
Harman, Ann E., Keegan, Mark T. , Macario, Alex, Minhaj, Mohammed , Chaudhry, Humayun J. , Young, Aaron , Zhou, Yan , Sun, Huaping , Wang, Ting , Warner, David O.

Mayo Clinic

Anesthesia & Analgesia | January 14, 2021 | Volume: 132 | Issue: 5 | Pages: 1457-1464

10.1213/ane.0000000000005332 | PMID 33438967 Get It

BACKGROUND: A temporary decrease in anesthesiology residency graduates that occurred around the turn of the millennium may have workforce implications. The aims of this study are to describe, between 2005 and 2015, (1) demographic changes in the workforce of physicians trained as anesthesiologists; (2) national and state densities of these physicians, as well as temporal changes in the densities; and (3) retention of medical licenses by mid- and later-career anesthesiologists. METHODS: Using records from the American Board of Anesthesiology and state medical and osteopathic boards, the numbers of licensed physicians aged 30–59 years who had completed Accreditation Council for Graduate Medical Education–accredited anesthesiology residency training were calculated cross-sectionally for 2005, 2010, and 2015. Demographic trends were then described. Census data were used to calculate national and state densities of licensed physicians. Individual longitudinal data were used to describe retention of medical licenses among older physicians. RESULTS: The number of licensed physicians trained as anesthesiologists aged 30–59 years increased from 32,644 in 2005 to 36,543 in 2010 and 36,624 in 2015, representing a national density of 1.10, 1.18, and 1.14 per 10,000 population in those years, respectively. The density of anesthesiologists among states ranged from 0.37 to 3.10 per 10,000 population. The age distribution differed across the years. For example, anesthesiologists aged 40–49 years predominated in 2005 (47%), but by 2015, only 31% of anesthesiologists were aged 40–49 years. The proportion of female anesthesiologists grew from 22% in 2005, to 24% in 2010, and to 28% in 2015, particularly among early-career anesthesiologists. For anesthesiologists with licenses in 2005, the number who still had active licenses in 2015 decreased by 9.6% for those aged 45–49 years, by 14.1% for those aged 50–54 years, and by 19.7% for those aged 55–59 years. CONCLUSIONS: The temporary decrease in anesthesiology residency graduates around the turn of the 21st century decreased the proportion of anesthesiologists who were midcareer as of 2015. This may affect the future availability of senior leaders as well as the future overall workforce in the specialty as older anesthesiologists retire. National efforts to plan for workforce needs should recognize the geographical variability in the distribution of anesthesiologists.
STIM1 Mediates Calcium-Dependent Epigenetic Reprogramming in Pancreatic Cancer
Kutschat, Ana P. , Hamdan, Feda H. , Wang, Xin , Wixom, Alexander Q. , Najafova, Zeynab , Gibhardt, Christine S. , Kopp, Waltraut, Gaedcke, Jochen , Ellenrieder, Volker , Heßmann, Elisabeth , Johnsen, Steven A. , Johnsen, Steven A , Najafova, Zeynab , Kutschat, Ana Patricia , Wixom, Alexander Q , Ströbel, Philipp , Bogeski, Ivan

Mayo Clinic

Cancer Research | January 12, 2021 | Volume: 81 | Issue: 11 | Pages: 2943-2955

10.1158/0008-5472.can-20-2874 | PMID 33436389 Get It

Abstract Pancreatic ductal adenocarcinoma (PDAC) displays a dismal prognosis due to late diagnosis and high chemoresistance incidence. For advanced disease stages or patients with comorbidities, treatment options are limited to gemcitabine alone or in combination with other drugs. While gemcitabine resistance has been widely attributed to the levels of one of its targets, RRM1, the molecular consequences of gemcitabine resistance in PDAC remain largely elusive. Here we sought to identify genomic, epigenomic, and transcriptomic events associated with gemcitabine resistance in PDAC and their potential clinical relevance. We found that gemcitabine-resistant cells displayed a coamplification of the adjacent RRM1 and STIM1 genes. Interestingly, RRM1, but not STIM1, was required for gemcitabine resistance, while high STIM1 levels caused an increase in cytosolic calcium concentration. Higher STIM1-dependent calcium influx led to an impaired endoplasmic reticulum stress response and a heightened nuclear factor of activated T-cell activity. Importantly, these findings were confirmed in patient and patient-derived xenograft samples. Taken together, our study uncovers previously unknown biologically relevant molecular properties of gemcitabine-resistant tumors, revealing an undescribed function of STIM1 as a rheostat directing the effects of calcium signaling and controlling epigenetic cell fate determination. It further reveals the potential benefit of targeting STIM1-controlled calcium signaling and its downstream effectors in PDAC. Significance: Gemcitabine-resistant and some naïve tumors coamplify RRM1 and STIM1, which elicit gemcitabine resistance and induce a calcium signaling shift, promoting ER stress resistance and activation of NFAT signaling.
Radiological Society of North America/Quantitative Imaging Biomarker Alliance Shear Wave Speed Bias Quantification in Elastic and Viscoelastic Phantoms
Palmeri, Mark L. , Milkowski, Andy , Barr, R. Graham , Carson, Paul L. , Couade, Mathieu , Chen, Shigao , Dhyani, Manish , Ehman, Richard L. , Garra, Brian S. , Gee, Albert, Guenette, Gilles, Hah, Zaegyoo , Lynch, Ted , Macdonald, Michael , Managuli, Ravi , Nightingale, Kathryn R. , Obuchowski, Nancy A. , Rouze, Ned C. , Morris, D. Cody , Fielding, Shana, Chan, Derek Y. , Choudhury, Kingshuk Roy , Yang, Siyun , Shamdasani, Vijay, Wear, Keith A. , Xie, Hua , Qiang, Bo, Rosenzweig, Stephen, Okamura, Yoko, McLaughlin, Glen, Chen, Yuling , Napolitano, David , Carlson, Lindsey , Erpelding, Todd N. , Barr, Richard , Carson, Paul , Dhyani, Manish , Ehman, Richard , Hah, Zaegyoo , Lynch, Ted , Macdonald, Michael , Managuli, Ravi , Miette, Veronique , Nightingale, Kathryn R , Obuchowski, Nancy , Rouze, Ned C , Morris, D Cody , Deng, Yufeng , Chan, Derek , Choudhury, Kingshuk , Samir, Anthony E , Urban, Matthew W , Wear, Keith , Ozturk, Arinc , Song, Pengfei , McAleavey, Stephen , Napolitano, David , Carlson, Lindsey , Hall, Timothy J , Chen, Jun , Miette, Véronique , Urban, Matthew W. , Song, Pengfei , Wang, Michael , Hall, Timothy J.

Mayo Clinic

Journal of Ultrasound in Medicine | January 10, 2021 | Volume: 40 | Issue: 3 | Pages: 569-581

10.1002/jum.15609 | PMID 33410183 Get It

ObjectivesTo quantify the bias of shear wave speed (SWS) measurements between different commercial ultrasonic shear elasticity systems and a magnetic resonance elastography (MRE) system in elastic and viscoelastic phantoms.MethodsTwo elastic phantoms, representing healthy through fibrotic liver, were measured with 5 different ultrasound platforms, and 3 viscoelastic phantoms, representing healthy through fibrotic liver tissue, were measured with 12 different ultrasound platforms. Measurements were performed with different systems at different sites, at 3 focal depths, and with different appraisers. The SWS bias across the systems was quantified as a function of the system, site, focal depth, and appraiser. A single MRE research system was also used to characterize these phantoms using discrete frequencies from 60 to 500 Hz.ResultsThe SWS from different systems had mean difference 95% confidence intervals of ±0.145 m/s (±9.6%) across both elastic phantoms and ± 0.340 m/s (±15.3%) across the viscoelastic phantoms. The focal depth and appraiser were less significant sources of SWS variability than the system and site. Magnetic resonance elastography best matched the ultrasonic SWS in the viscoelastic phantoms using a 140 Hz source but had a − 0.27 ± 0.027‐m/s (−12.2% ± 1.2%) bias when using the clinically implemented 60‐Hz vibration source.ConclusionsShear wave speed reconstruction across different manufacturer systems is more consistent in elastic than viscoelastic phantoms, with a mean difference bias of < ±10% in all cases. Magnetic resonance elastographic measurements in the elastic and viscoelastic phantoms best match the ultrasound systems with a 140‐Hz excitation but have a significant negative bias operating at 60 Hz. This study establishes a foundation for meaningful comparison of SWS measurements made with different platforms.
Tissue-resident CD4 + T helper cells assist the development of protective respiratory B and CD8 + T cell memory responses
Son, Young Min , Cheon, In Su , Wu, Yue , Li, Chaofan , Wang, Zheng , Gao, Xiaochen , Takahashi, Yoshimasa , Fu, Yang-Xin , Dent, Alexander L. , Kaplan, Mark H. , Fu, Yang‐Xin , Fu, Yang-Xin , Dent, Alexander L , Kaplan, Mark H , Taylor, Justin J , Sun, Jie , Li, Chaofan , Chen, Yao , Taylor, Justin J. , Cui, Weiguo , Sun, Jie

Mayo Clinic

Science Immunology | January 8, 2021 | Volume: 6 | Issue: 55 | Pages: No page available

10.1126/sciimmunol.abb6852 | PMID 33419791 Get It

Identification of a CD4 + helper T cell population providing in situ help to B and CD8 + T cells in the respiratory mucosa.
Author response: MYC regulates ribosome biogenesis and mitochondrial gene expression programs through its interaction with host cell factor–1
Codreanu, Simona G. , Thomas, Lance R. , Lorey, Shelly L. , Machida, Yuichi , Popay, Tessa M. , Wang, Jing , Adams, Clare M. , Howard, Gregory C. , Sherrod, Stacy D. , McLean, John A. , Weissmiller, April M. , Eischen, Christine M. , Liu, Qi , Tansey, William P

Mayo Clinic

No container title available | January 8, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.60191.sa2 Get It

MYC regulates ribosome biogenesis and mitochondrial gene expression programs through its interaction with host cell factor–1
Popay, Tessa M. , Howard, Gregory C. , Codreanu, Simona G. , Sherrod, Stacy D. , McLean, John A. , Thomas, Lance R. , Lorey, Shelly L. , Machida, Yuichi , Weissmiller, April M. , Eischen, Christine M. , Sherrod, Stacy D , Machida, Yuichi J, Eischen, Christine M , Tansey, William P , Wang, Jing , Adams, Clare M. , Liu, Qi

Mayo Clinic

eLife | January 8, 2021 | Volume: 10 | Issue: No issue available | Pages: No page available

10.7554/elife.60191 | PMID 33416496 Get It

The oncoprotein transcription factor MYC is a major driver of malignancy and a highly validated but challenging target for the development of anticancer therapies. Novel strategies to inhibit MYC may come from understanding the co-factors it uses to drive pro-tumorigenic gene expression programs, providing their role in MYC activity is understood. Here we interrogate how one MYC co-factor, host cell factor (HCF)–1, contributes to MYC activity in a human Burkitt lymphoma setting. We identify genes connected to mitochondrial function and ribosome biogenesis as direct MYC/HCF-1 targets and demonstrate how modulation of the MYC–HCF-1 interaction influences cell growth, metabolite profiles, global gene expression patterns, and tumor growth in vivo. This work defines HCF-1 as a critical MYC co-factor, places the MYC–HCF-1 interaction in biological context, and highlights HCF-1 as a focal point for development of novel anti-MYC therapies.
HDAC5 Loss Impairs RB Repression of Pro-Oncogenic Genes and Confers CDK4/6 Inhibitor Resistance in Cancer
Zhou, Yingke , Jin, Xin , Ding, Donglin , Huang, Zhenlin, Sheng, Haoyue , Yan, Yuqian , Pan, Yunqian , Wei, Ting , Wang, Liguo , Wu, Heshui , Huang, Haojie , Huang, Rui , Wang, Liguo , Wei, Ting , Jin, Xin , Ma, Jian

Mayo Clinic

Cancer Research | January 8, 2021 | Volume: 81 | Issue: 6 | Pages: 1486-1499

10.1158/0008-5472.can-20-2828 | PMID 33419772 Get It

Abstract The tumor-suppressor protein RB acts as a transcription repressor via interaction of its pocket domain with an LXCXE motif in histone deacetylase (HDAC) proteins such as HDAC1. Here, we demonstrate that HDAC5 deficient for the LXCXE motif interacts with both RB-N (via an FXXXV motif) and RB-C segments, and such interactions are diminished by phosphorylation of RB serine-249/threonine-252 and threonine-821. HDAC5 was frequently downregulated or deleted in human cancers such as prostate cancer. Loss of HDAC5 increased histone H3 lysine 27 acetylation (H3K27-ac) and circumvented RB-mediated repression of cell-cycle–related pro-oncogenic genes. HDAC5 loss also conferred resistance to CDK4/6 inhibitors such as palbociclib in prostate and breast cancer cells in vitro and prostate tumors in vivo, but this effect was overcome by the BET-CBP/p300 dual inhibitor NEO2734. Our findings reveal an unknown role of HDAC5 in RB-mediated histone deacetylation and gene repression and define a new mechanism modulating CDK4/6 inhibitor therapeutic sensitivity in cancer cells. Significance: This study defines a previously uncharacterized role of HDAC5 in tumor suppression and provides a viable strategy to overcome CDK4/6 inhibitor resistance in HDAC5-deficent cancer.
Integrated Molecular Characterization of Fumarate Hydratase–deficient Renal Cell Carcinoma
Sun, Guangxi , Liang, Jiayu, Pan, Xiuyi , Zhu, Sha , Liu, Zhenhua, Armstrong, Cameron M. , Lin, Wei, Liao, Banghua , Lin, Tianhai , Zhang, Mengni , Zheng, Linmao , Yin, Xiaoxue , Shen, Pengfei , Zhao, Jinge , Dai, Jindong, Shen, Yali, Li, Zhiping , Liu, Jiyan , Chen, Junru , Ni, Yuchao , Qin, Dan , Yang, Ling , Wei, Qiang , Li, Xiang , Zhou, Qiao , Yao, Jin , Chen, Ni , Zeng, Hao , Wang, Zhipeng , Liu, Zhenhua , Huang, Rui , Shen, Pengfei , Zhu, Sha , Chen, Junru , Wang, Zhipeng , Zhang, Xingming , Chen, Jianhui , Lin, Wei, Nie, Ling , Zhang, Haoran , Wang, Zhipeng , Zhu, Xudong , Chen, Yahong , Huang, Haojie

Mayo Clinic

Clinical Cancer Research | January 7, 2021 | Volume: 27 | Issue: 6 | Pages: 1734-1743

10.1158/1078-0432.ccr-20-3788 | PMID 33414138 Get It

AbstractPurpose:Fumarate hydratase–deficient renal cell carcinoma (FH-deficient RCC) is a rare but lethal subtype of RCC. Little is known about the genomic profile of FH-deficient RCC, and the therapeutic options for advanced disease are limited. To this end, we performed a comprehensive genomics study to characterize the genomic and epigenomic features of FH-deficient RCC.Experimental Design:Integrated genomic, epigenomic, and molecular analyses were performed on 25 untreated primary FH-deficient RCCs. Complete clinicopathologic and follow-up data of these patients were recorded.Results:We identified that FH-deficient RCC manifested low somatic mutation burden (median 0.58 mutations per megabase), but with frequent somatic copy-number alterations. The majority of FH-deficient RCCs were characterized by a CpG sites island methylator phenotype, displaying concerted hypermethylation at numerous CpG sites in genes of transcription factors, tumor suppressors, and tumor hallmark pathways. However, a few cases (20%) with low metastatic potential showed relatively low DNA methylation levels, indicating the heterogeneity of methylation pattern in FH-deficient RCC. Moreover, FH-deficient RCC is potentially highly immunogenic, characterized by increased tumor T-cell infiltration but high expression of immune checkpoint molecules in tumors. Clinical data further demonstrated that patients receiving immune checkpoint blockade–based treatment achieved improved progression-free survival over those treated with antiangiogenic monotherapy (median, 13.3 vs. 5.1 months; P = 0.03).Conclusions:These results reveal the genomic features and provide new insight into potential therapeutic strategies for FH-deficient RCC.
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021
Altman, Jessica K. , Assi, Rita, Bachiashvili, Kimo, Fathi, Amir T. , Fedorov, Kateryna, Foran, James M. , Gojo, Ivana , Goldberg, Aaron, Hall, Aric C. , Jonas, Brian A., Levine, Matthew R., Mangan, James, Mannis, Gabriel N. , Marcucci, Guido , Moriarty, Kelsey, Ali, Moaath Mustafa, Neff, Jadee , Nejati, Reza , Olin, Rebecca L. , Patel, Anand, Percival, Mary‐Elizabeth M. , Perl, Alexander E. , Pettit, Kristen, Rao, Dinesh S. , Ravandi‐Kashani, Farhad, Schwabkey, Zaker, Shallis, Rory, Stahl, Maximilian, Stone, Richard M. , Thota, Swapna, Uy, Geoffrey L., Walker, Alison, Wang, Eunice, Awotiwon, Ajibola, Roth, Sydney L., Stehman, Katie, Strickland, Stephen A. , Przespolewski, Amanda , Strickland, Stephen Anthony , Pollyea, Daniel Aaron , Assi, Rita, Bachiashvili, Kimo, Bhatt, Vijaya Raj , Fedorov, Kateryna, Goldberg, Aaron, Jonas, Brian A., Levine, Matthew R., Mangan, James, Mims, Alice S , Moriarty, Kelsey, Ali, Moaath Mustafa, Patel, Anand, Pettit, Kristen, Schwabkey, Zaker, Shallis, Rory, Stahl, Maximilian, Thota, Swapna, Uy, Geoffrey L., Walker, Alison, Wang, Eunice, Awotiwon, Ajibola, Roth, Sydney L., Stehman, Katie

Mayo Clinic

Journal of the National Comprehensive Cancer Network | January 6, 2021 | Volume: 19 | Issue: 1 | Pages: 16-27

10.6004/jnccn.2021.0002 | PMID 33406488 Get It

The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regarding factors with prognostic importance, and are intended to aid physicians with clinical decision-making. These NCCN Guidelines Insights focus on recent select updates to the NCCN Guidelines, including familial genetic alterations in AML, postinduction or postremission treatment strategies in low-risk acute promyelocytic leukemia or favorable-risk AML, principles surrounding the use of venetoclax-based therapies, and considerations for patients who prefer not to receive blood transfusions during treatment.